To resolve the current controversies regarding the use of GLP-1 RAs in treating hypertension and ischemic cardiomyopathy, large-scale clinical RCTs or real-world studies should be designed to provide more robust evidence
Tirzepatide (Zepbound/Mounjaro) is a newer dual-action GIP/GLP-1 agonist that targets two hormonal pathways for even greater results
[27] Warnings/Precautions: [edit] Pancreatitis has been reported in clinical trials, do not continue usage if any pancreatitis has been spotted or confirmed, other therapies should be considered in patients with a prior history of pancreatitis Hypoglycemia has been noted when used in combination with an insulin secretagogue or insulin, consider lowering the usage of insulin in order to reduce the risk of hypoglycemia Hypersensitivity reactions such as anaphylactic reactions and angioedema have occurred
Common Endpoints by Route Endpoint Skin firmness or smoothness Topical timeline 8-12 weeks Injectable framing Anecdotal
This would result in the optimization of both, patient-related and procedural, outcomes
This lowers the chance of nausea, dizziness, or headaches